Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2022 Jan 5;18(1):e1010182. doi: 10.1371/journal.ppat.1010182

Structure of a bacterial Rhs effector exported by the type VI secretion system

Patrick Günther 1,#, Dennis Quentin 1,#, Shehryar Ahmad 2, Kartik Sachar 2, Christos Gatsogiannis 1,¤, John C Whitney 2,3,4,*, Stefan Raunser 1,*
Editor: Karla JF Satchell5
PMCID: PMC8765631  PMID: 34986192

Abstract

The type VI secretion system (T6SS) is a widespread protein export apparatus found in Gram-negative bacteria. The majority of T6SSs deliver toxic effector proteins into competitor bacteria. Yet, the structure, function, and activation of many of these effectors remains poorly understood. Here, we present the structures of the T6SS effector RhsA from Pseudomonas protegens and its cognate T6SS spike protein, VgrG1, at 3.3 Å resolution. The structures reveal that the rearrangement hotspot (Rhs) repeats of RhsA assemble into a closed anticlockwise β-barrel spiral similar to that found in bacterial insecticidal Tc toxins and in metazoan teneurin proteins. We find that the C-terminal toxin domain of RhsA is autoproteolytically cleaved but remains inside the Rhs ‘cocoon’ where, with the exception of three ordered structural elements, most of the toxin is disordered. The N-terminal ‘plug’ domain is unique to T6SS Rhs proteins and resembles a champagne cork that seals the Rhs cocoon at one end while also mediating interactions with VgrG1. Interestingly, this domain is also autoproteolytically cleaved inside the cocoon but remains associated with it. We propose that mechanical force is required to remove the cleaved part of the plug, resulting in the release of the toxin domain as it is delivered into a susceptible bacterial cell by the T6SS.

Author summary

Bacteria have developed a variety of strategies to compete for nutrients and limited resources. One system widely used by Gram-negative bacteria is the T6 secretion system which delivers a plethora of effectors into competing bacterial cells. Known functions of effectors are degradation of the cell wall, the depletion of essential metabolites such as NAD+ or the cleavage of DNA. RhsA is an effector from the widespread plant-protecting bacteria Pseudomonas protegens. We found that RhsA forms a closed cocoon similar to that found in bacterial Tc toxins and metazoan teneurin proteins. The effector cleaves its polypeptide chain by itself in three pieces, namely the N-terminal domain including a seal, the cocoon and the actual toxic component which potentially cleaves DNA. The toxic component is encapsulated in the large cocoon, so that the effector producing bacterium is protected from the toxin. In order for the toxin to exit the cocoon, we propose that the seal, which closes the cocoon at one end, is removed by mechanical forces during injection of the effector by the T6 secretion system. We further hypothesize about different scenarios for the delivery of the toxin into the cytoplasm of the host cell. Together, our findings expand the knowledge of the mechanism of action of the T6 secretion system and its essential role in interbacterial competition.

Introduction

One way that bacteria interact with their environment is by secreting toxic molecules into their surroundings. Many species of Gram-negative bacteria have evolved specialized protein secretion systems for this purpose with arguably the best-characterized example being the T6SS [1,2]. T6SSs mediate bacterial antagonism by facilitating the injection of toxic effector proteins into competing bacterial cells in a contact-dependent manner [3].

A functional T6SS apparatus requires the concerted action of three protein subcomplexes: a cell envelope-spanning membrane complex, a cytoplasmic baseplate complex and a bacteriophage tail-like sheath-tube complex [4,5]. The tail-like complex consists of a contractile sheath that surrounds an inner tube comprised of many copies of stacked ring-shaped hexameric hemolysin co-regulated protein (Hcp) [6,7]. This Hcp tube is capped with a member of the homotrimeric valine-glycine repeat protein G (VgrG) spike protein family, which typically also interacts with a cone-shaped proline-alanine-alanine-arginine (PAAR) domain-containing protein to form a complete T6SS tail tube-spike complex [8]. During a T6SS firing event, the Hcp-VgrG-PAAR tube-spike complex is rapidly assembled in the cytosol of the attacking bacterium, recruited to the membrane complex through its interaction with the baseplate, and subsequently surrounded by a contractile sheath that upon sheath contraction, propels the tail spike into the recipient cell [9]. Toxic effector proteins are recruited to the tube-spike complex and injected into recipient cells alongside Hcp and VgrG, typically resulting in death of the target cell. Self-protection from antibacterial T6SS effectors is accomplished via effector co-expression with cognate immunity proteins, which neutralize effector toxicity by occluding the effector active site or by the hydrolysis of effector generated toxic products [10,11].

Effectors are recruited to distinct regions of the T6SS tube-spike complex. Smaller effectors (< 50 kDa) are typically recognized and loaded within the lumen of the Hcp tube [12] whereas larger, multidomain effectors interact with VgrG proteins via an effector-encoded PAAR domain or by directly interacting with VgrG itself [13]. PAAR-containing effectors are widely distributed in Proteobacteria and can be further subdivided into subfamilies of proteins based on the presence of additional sequence motifs that may play a role in effector translocation into target cells. One family of PAAR effectors that was recently described in detail possess an additional N-terminal motif, called prePAAR, predicted to be involved in PAAR folding, as well as at least one N-terminal transmembrane domain (TMD) that is hypothesized to insert into the recipient cell inner membrane with one to three transmembrane helices per TMD that enable toxin translocation into the cytoplasm [14]. TMD-containing PAAR effectors require effector-associated gene (Eag) chaperones to bind and stabilize effector TMDs prior to export from the donor cell [14,15].

Previously, our group showed that the T6SS of the soil bacterium Pseudomonas protegens secretes the prePAAR and PAAR-containing effector RhsA [14]. The rhsA operon contains genes encoding its cognate VgrG spike and Eag chaperone proteins (Fig 1A), both of which are required for the delivery of this effector into susceptible competitors [14]. Previous negative stain electron microscopy experiments suggest that EagR1, RhsA and VgrG assemble to form a complex necessary for T6SS function (Fig 1B) [14]. The N-terminus of RhsA consists of a prePAAR motif as well as two predicted transmembrane helices within its TMD. The prePAAR motif is proposed to contribute sequence elements that ‘complete’ the PAAR domain and enable its interaction with the tip of VgrG1 [14] whereas the transmembrane helices likely play a role in target cell penetration [16].

Fig 1. High-resolution structure of the T6SS effector RhsA.

Fig 1

(A) Genomic context of rhsA (PFL_6096, blue) in Pseudomonas protegens Pf-5. Upstream genes encoding the cognate VgrG protein, vgrG1 (PFL_6094, green) and RhsA-specific chaperone, eagR1 (PFL_6095, light brown) are shown. Self-protection against RhsA is conferred via expression of the downstream immunity-encoding gene, rhsI (dark brown). (B) Representative cryo-EM 2-D class averages of the assembled pre-firing complex composed of VgrG1, RhsA and EagR1 (left) and a schematic representation of each of the components that comprise this complex (right). Scale bar, 10 nm. (C) Full-length RhsA contains a prePAAR motif and a TMD comprising two transmembrane helices upstream of its PAAR domain. The RhsAΔTMD truncation of RhsA was used in this study to determine the high-resolution structure of the RhsA cocoon. (D) Cryo-EM density of RhsAΔTMD displayed perpendicular to the central symmetry axis of the barrel and rotated 90° clockwise (map postprocessed with DeepEMhancer). (E) Cartoon representation of the atomic model of RhsA colored in rainbow from N-terminus (blue) to C-terminus (red).

In addition to its N-terminal prePAAR, TMD and PAAR regions, RhsA possesses Rhs elements, which are characterized by the presence of repeating tyrosine-aspartate (YD) motifs. The chromosomal regions encoding Rhs repeats were originally described in Escherichia coli genomes as sites where recombination frequently took place [17]. Later studies revealed that Rhs repeat-containing proteins are not unique to E. coli but are common across Proteobacteria [18,19]. Other more distant homologs, called teneurins, are involved in axon guidance in vertebrates [2022]. Teneurins are type II single-pass transmembrane proteins that mediate cell-cell adhesion via their Rhs repeat-containing extracellular domains [23,24]. The intracellular domain consists of a transcriptional repressor that is released from the membrane upon proteolytic cleavage. The extracellular epidermal growth factor-like repeats (EGF) mediate covalent dimerization by formation of disulphide bridges [21,25]. Structures of bacterial Rhs proteins and the extracellular domain of human teneurin2 revealed that Rhs repeat regions form a large (~100 kDa) β-barrel cocoon-like structure spirally wound counterclockwise [2629]. The C-terminus of the Rhs barrel is typically demarcated by a highly conserved PxxxxDPxGL motif, which is necessary for autoproteolytic cleavage [20]. Previous work has shown that C-terminal autoproteolysis of both T6SS Rhs effectors and toxin complex (Tc) Rhs toxins is required for toxin release from the Rhs cocoon [26,27,30].

Tc toxins consist of three components: a 1.4 MDa homopentameric A component (TcA), a ~170 kDa TcB subunit and a ~100 kDa TcC subunit [26]. TcA acts as membrane permeation and translocation device, while TcB and TcC together form a large hollow cocoon composed of Rhs repeats. The C-terminal extension of the TcC subunit lies inside the cocoon and is autocatalytically processed by an aspartyl protease [26]. While the Rhs repeat-containing region is highly conserved among T6SS Rhs effectors and Tc toxins, their N- and C-terminal extensions can differ significantly. The C-terminus of bacterial Rhs proteins encode for a diverse range of toxins and is often referred to as the hypervariable region (HVR) [31]. In Tc toxins, the C-terminal toxin is encapsulated within the Rhs cocoon [32], however, previous structural analyses of these proteins have been unable to resolve the structure of a HVR, suggesting that this region may be partially unfolded. So far, no high-resolution structural information exists for T6SS Rhs effectors.

The Rhs repeat-containing cocoon TcBC interacts through the β-propeller domain of TcB with TcA. The propeller acts as a gate that opens upon A component binding, allowing the HVR to enter the translocation channel of TcA [32]. The penetration of the target cell membrane through the A component is triggered by either a shift to higher or lower pH [26]. Membrane penetration opens the translocation channel of TcA, which permits subsequent HVR release into the prey cell cytosol [26,33]. A similarly detailed toxin release mechanism has not been reported for the bacteria targeting T6SS Rhs effectors [3] and structures of T6SS-exported Rhs proteins have not been determined to date.

In this work, we present high-resolution structures of the T6SS effector RhsA and its cognate VgrG1 protein at resolutions of 3.3 Å. The structure of VgrG1 is nearly identical to our previously determined VgrG1 structure from P. aeruginosa [16], indicating a high structural conservation of VgrG proteins. The structure of RhsA reveals that the Rhs-repeats of RhsA form a cocoon similar to that of the B and C components of Tc toxins and teneurins. However, unlike the cocoon of Tc toxins, which are capped by the aforementioned β-propeller domain, RhsA is closed at its N-terminus by a plug domain that connects the cocoon to its N-terminal PAAR domain. The plug domain is held in place via hydrophobic interactions with the Rhs cocoon and its eventual opening is the most likely event for the toxin domain to be released from the barrel. Our structural and biochemical findings show that the plug domain is autoproteolytically cleaved inside the cocoon. The cleaved 304 N-terminal residues, comprising the prePAAR motif, TMD, and PAAR domain also include an N-terminal seal peptide of the Rhs plug and an anchor helix. This helix interacts extensively with the inner surface of the cocoon and is likely responsible for keeping the cleaved N-terminal 304 residues physically associated with the cocoon. In addition, we find that the RhsA C-terminal toxin domain is also cleaved via a canonical Rhs aspartyl autoprotease and that this cleavage event is required for RhsA-dependent bacterial killing. Taken together, our results provide novel insights into the architecture and mechanism of action of Rhs effectors exported by the T6SS.

Results and discussion

RhsA forms a cocoon-like structure that undergoes N- and C-terminal autocleavage

We previously demonstrated that a fragment of RhsA lacking its N-terminal prePAAR motif and TMD (Fig 1C, residues 74–1486), RhsAΔTMD, is stable in the absence of its EagR1 chaperone and can be purified to homogeneity as a soluble protein when over-expressed in Escherichia coli [14]. We therefore expressed and purified RhsAΔTMD (S1A Fig) and used it for cryo-EM and single particle analysis. The raw images and 2D class averages suggest that RhsAΔTMD forms a stable dimer in solution, which facilitated structure determination due to the increased size of the particles. Subsequent image processing imposing C2 symmetry resulted in a reconstruction with a resolution of 3.3 Å from 454,740 particles (Fig 1D and Table 1). The high quality of the map allowed us to build an atomic model of 75% of the protein, comprising residues 268–275, 289–302, 305–366, 371–386, 395–871, 891–1039 and 1051–1350 (Fig 1E). The 25% of remaining unresolved regions correspond to the PAAR domain (residues 75–267) and the toxin domain (residues 1351–1486), indicating that these regions likely exhibit a high degree of flexibility.

Table 1. Statistics of cryo-EM data collection, image processing and model validation.

VgrG1 RhsAΔTMD
Data collection
Microscope Titan Krios (X-FEG, Cs-corrected) Titan Krios (X-FEG, Cs 2.7 mm)
Magnification 59,000 105,000
Voltage (kV) 300 300
Defocus range (μm) -1.2 to -2.2 -0.8 to -2.2
Camera F3 linear K3 counting
Pixel size (Å/pixel) 1.1 0.91
Total electron dose (e2) 90 62
Exposure time (s) 1.5 2
Number of images 1250 13,090
Refinement
Number of final particles 423,980 454,740
Final resolution (Å) 3.3 3.3
Symmetry C 3 C 2
Map sharpening B factor (Å2) -174.5 DeepEMhancer
Model composition
Non-hydrogen atoms 14868 17070
Protein residues 1881 2094
RMSD bond 0.007 0.006
RMSD angles 0.722 0.570
Model-to-map fit, CC Mask 0.77 0.77
Validation
MolProbity 1.85 1.42
Clashscore 6.86 4.15
EMRinger score 2.77 4.70
Poor rotamers (%) 0.00 0.45
Ramachandran
Favored (%) 92.46 96.59
Allowed (%) 7.22 3.31
Outliers (%) 0.32 0.10

The two molecules in the RhsAΔTMD dimer interact along their longitudinal axes and are slightly tilted with respect to one another. The dimer interface is comprised of several complementary hydrophilic surfaces indicating that it is mostly electrostatic in nature (S2A and S2B Fig). The 76 antiparallel β-strands of RhsAΔTMD spiral in an anticlockwise manner resulting in a large hollow cocoon-shaped structure with outer dimensions of 86 x 65 Å. The overall structure of the Rhs cocoon resembles that of other YD-repeat containing proteins, such as the BC component of Tc toxins [26,27] and human teneurin2 [28]. We also identified the conserved catalytic center of an aspartyl autoprotease that was first identified in Tc toxins [26,27]. In line with functioning to self-cleave the C-terminal toxin domain, we observed that the density of the cryo-EM map stops abruptly after tryptophan 1350 (Fig 2A). This position is in agreement with cleavage sites in other Rhs-related toxins that share the same PxxxxDPxG W/L/F consensus sequence found in RhsA (S3A Fig), indicating that the C-terminal toxin domain is likely autoproteolytically cleaved similar to the HVR found in Tc toxins. To experimentally test the proteolytic activity of this motif, we mutated either aspartate 1324 or aspartate 1346, which are the RhsA residues in the equivalent position to the catalytic dyad of Tc toxin aspartyl autoproteases, to asparagine. Consistent with their proposed role in autocleavage and toxin release, these RhsA variants did not undergo autoproteolysis at their C-terminus (Fig 2B) and were substantially less toxic when overexpressed in E. coli compared to the wild-type protein (S3B Fig). We next introduced these mutations into the chromosome of P. protegens to test whether C-terminal autoproteolytic cleavage is indeed required for interbacterial competition. In contrast to a strain expressing wild-type RhsA, strains expressing the D1324N or D1346N variants of the protein were unable to outcompete RhsA-sensitive recipient bacteria indicating that C-terminal autocleavage is required for T6SS-dependent killing by this effector (Fig 2C). These findings mirror what has been observed for T6SS-exported Rhs proteins in Aeromonas dhakensis and Enterobacter cloacae suggesting that toxin domain liberation is a universal property of Rhs effectors [18,34].

Fig 2. Autoproteolysis of RhsA occurs at its N- and C-terminus.

Fig 2

(A) RhsA is autoproteolytically cleaved at its C-terminus at position W1350. The end of the connected density is indicated with an asterisk. Catalytic aspartates D1324 and D1346, are shown in stick representation. (B) Western blot analysis shows proteolytic cleavage of the C-terminal toxin domain. Mutation of either D1324 or D1346 to asparagine prevents autoproteolytic cleavage of the C-terminal RhsA toxin domain. Blots were performed against the Rhs barrel (α-RhsA) and against a C-terminal VSV-G epitope tag (α-VSV-G). (C) Outcome of intraspecific growth competition assays between the indicated P. protegens donor and recipient strains. Donor strains were competed against recipient strains that either contain (light grey) or lack the rhsA-rhsI effector-immunity pair (dark grey). The recipient strains also lack pppA to stimulate type VI secretion in donors [14]. Data are mean ± s.d. for n = 3 biological replicates and are representative of two independent experiments. (D) The toxin domain of RhsA is encapsulated by its cocoon-shaped Rhs repeat-containing domain. Difference map of the encapsulated toxin at extremely low-density threshold and low pass-filtered to 20 Å (green) is shown. The Rhs cocoon is depicted using a transparent space-filling representation at normal map threshold. (E) Regions of the toxin domain are stabilized inside the cocoon through interactions with the C-terminal autoprotease domain. The densities appear at the same density threshold as the rest of the map. The atomic models are shown in stick representation. (F) RhsA undergoes N-terminal cleavage at proline 305. The end of the density is indicated with an asterisk. (G) N-terminal cleavage occurs in RhsA and a mutant lacking the prePAAR-TMD (RhsAΔTMD, residues 74-CT) but not in a mutant lacking the entire N-terminal region (RhsAΔN, residues 297-CT). The indicated RhsA constructs were purified from E. coli and subject to Western blot and detected using an N-terminal His6-tag antibody (α-his6).

We also identified additional density inside the Rhs cocoon corresponding to the C-terminal toxin domain, which is predicted to function as a DNase based on its sequence similarity to several characterized endonucleases and homology to other characterized Rhs effectors [35]. The density filling the cocoon is, for the most part, not well defined and is apparent only at a much lower density threshold compared to the rest of the map (Fig 2D), Nevertheless, we could build three β-strands of this domain, comprising residues 1408–1413, 1420–1423 and 1458–1461, respectively, all of which interact with the inner surface of the cocoon structure (Fig 2E). The interface between the β-strands and the cocoon is stabilized by both hydrophilic and hydrophobic interactions (Figs 2E and S4). In sum, these structural data indicate that most of the toxin domain is either only partially folded or very flexible.

Interestingly, the density inside the Rhs cocoon not only ends after tryptophan 1350 but also before proline 305 (Fig 2F), suggesting that RhsA is proteolytically cleaved at this position as well. However, the N-terminal region is presumably still associated with the cocoon structure because the protein was purified by affinity chromatography using an N-terminal His-tag. Therefore, we heat-denatured RhsAWT and RhsAΔTMD prior to SDS-PAGE to determine if the N-terminal domain was indeed cleaved. Consistent with our structural data, we observed bands that migrate at molecular weights consistent with the loss of ~304 and ~230 amino acids, respectively, corresponding to the 304 N-terminal residues of RhsAWT and 230 N-terminal residues of RhsAΔTMD (Fig 2G). To unambiguously determine the position of the cleavage site we performed de novo protein sequencing via LC-MS/MS. We found that the N-terminal peptide of the Rhs-cocoon detected by mass spectrometry exactly matches the proposed cleavage site at proline 305 (S5A Fig). In addition, we further validated cleavage at this position by generating a non-cleavable version of RhsA in which both residues H304 and P305 were mutated to alanine. This RhsA variant was unable to undergo autoproteolysis at its N-terminus (S5B Fig). Collectively, these data demonstrate that the protein is indeed cleaved between residues 304 and 305. By contrast, a truncation of RhsA lacking this entire N-terminal region, RhsAΔN, did not undergo N-terminal proteolysis (Fig 2G). A similar observation was recently made for the T6SS effector TseI from A. dhakensis, which is also N-terminally cleaved even though it differs from RhsA at its N-terminus in that it lacks prePAAR, PAAR and a TMD [18]. This cleavage event was shown to be essential for the activity of TseI after its secretion by the T6SS. Two glutamate residues at the +7 and +8 position relative to the N-terminal cleavage site are responsible for the autoproteolysis of this effector [18]. However, these glutamates are not conserved in RhsA and are replaced by alanine (A312) and lysine (K313), which cannot act as catalytic center (S5C–S5E Fig). Therefore, we examined the direct vicinity of P305 in our structure and found a cysteine residue (C538) flanked by two histidines (H530 and H555) that protrude from the wall of the Rhs barrel and are located near proline 305 (S5F Fig). Unlike the previously described glutamate residues, this site is conserved in class I prePAAR T6SS Rhs effectors, but does not exist in Tc toxins (S5G Fig) [18]. In addition, we identified three consecutive aspartates (D318-D320) in close proximity to the cleavage site.

To test the hypothesis of whether cysteine 538 or the other proximal residues are involved in N-terminal cleavage, we mutated these residues individually and performed a Western blot analysis against the N-terminus of the overexpressed constructs (S5H Fig). Contrary to our assumption, we found that mutation of C538 to alanine did not abolish the N-terminal cleavage. Mutations of other conserved residues near the cleavage site had also little effect. Only the triple mutant (D318-D320 to alanine) led to a minimal reduction of N-terminal cleavage. However, we believe that this could be an indirect effect induced by the mutationally altered conformation in this region similar to the construct where we mutated H530 to alanine.

Since there are no other obvious potential catalytically active residues besides the tested ones, we speculated that the encapsulated C-terminal toxin domain could be involved in catalyzing the N-terminal cleavage reaction. To test this, we generated a truncated form of RhsA lacking its C-terminal toxin domain (RhsAΔtox) and examined N-terminal cleavage via Western blot. This analysis clearly showed that RhsAΔtox is still able to undergo autoproteolysis at the N-terminus (S5I Fig). Therefore, the N-terminal cleavage must occur via an as yet unknown mechanism.

RhsA possesses a unique plug domain at its N-terminus

Our structural data show that the C-terminal aspartyl protease domain of RhsA seals the cocoon-shaped structure at one end, while the other end is capped by an N-terminal domain that adopts a smaller structure. This N-terminal domain of the barrel, formed by residues 268–386, caps the cocoon structure in a manner that is reminiscent of how a cork is used to plug a champagne bottle and thus we refer to it as the N-terminal plug domain (RhsAplug) (Fig 3A–3E). The interface between the plug domain and the Rhs repeats is mainly stabilized by hydrophobic interactions (Fig 3A–3C) and a few hydrophilic interactions (S6A Fig).

Fig 3. A unique plug domain seals the Rhs barrel of RhsA.

Fig 3

(A) Surface representation of the cork domain of RhsA. The molecular surface is colored according to hydrophobicity where ochre and white indicate hydrophobic and hydrophilic regions, respectively. The Rhs barrel is shown as a cartoon. (B) Enlarged view of the cork domain of RhsA. The hydrophobic surface spirals around the domain as indicated by the black dashed line. (C) The upper Rhs repeats of RhsA possess complementary hydrophobic patches to those found on its plug domain (shown in cartoon representation, red). (D) The cocoon structure of RhsA is closed off by an N-terminal plug comprised of a ‘cork’ domain (orange, density representation), a ‘seal’ peptide (mesh), and an anchor helix (E, F). The seal and the cork density together form a cap structure. (E) The seal peptide, which also functions as the linker to the unmodelled PAAR domain, not only complements the shape of the cork but is also the entry point of the N-terminal part of the protein into the inside of the cocoon. The cocoon remains stably bound to the cleaved N-terminal region, including the PAAR domain, due to the anchor helix inside the cocoon. (F) The anchor helix of RhsA is stabilized by hydrophobic interactions with the inner wall of the Rhs repeats. (G) Cartoon representation of the cork region of the RhsA plug domain and a comparison with the homologous N-terminal plug domain of Photorhabdus luminescens TcdB2 (grey, PDB ID: 6H6G) and the unique FN-plug domain of human teneurin2 (green, PDB ID: 6FB3). The lower part of each depicted plug domain inserts into each of their respective Rhs barrels. The cork domain of RhsA is colored in rainbow.

In addition to the cork structure (residues 305–386), the plug domain contains an anchor helix (residues 289–302) and an N-terminal seal peptide (residues 268–275). The seal peptide fills a small opening in the cork as it leaves the cocoon and connects the plug domain to the unmodelled PAAR domain (Figs 3D–3E and S7A and S7B). In doing so, the seal peptide, together with the cork, closes off the cocoon entirely (S7B Fig). The anchor helix is amphipathic and stabilized by interactions with a hydrophobic patch of the Rhs repeats in this region (Figs 3E and 3F and S7C–S7E). The position of the anchor helix in our structure suggests its function is twofold. On the one hand it holds the N-terminal cleavage site in place. On the other hand, it ensures that the N-terminal plug domain remains stably attached to the cocoon, so that it remains sealed even after N-terminal cleavage.

The plug domain of RhsA possesses sequence and structural similarity to a domain found in the BC components of TcdB2-TccC3 [26] and YenBC [27] (Figs 3G and S8A–S8C) (18% sequence identity to TcdB2; 22% sequence identity to YenB). Interestingly, in Tc toxins this domain does not act as a plug that prevents the release of the toxin, but instead forms a negatively charged constriction through which the toxin domain is threaded prior to its translocation into a target cell [32]. A plug domain has also been described in teneurins (called fibronectin-plug, FN-plug) [28,29], however, it does not bear sequence or structural similarity to the plug domain of RhsA described herein. The FN-plug is narrower than the plug domains of RhsA and Tc toxins and extends further into the Rhs cocoon structure (Fig 3G) making numerous hydrophilic interactions with residues lining the inside of the YD-shell [28].

Our structure suggests that in contrast to Tc toxins the plug domain of RhsA tightly seals its Rhs cocoon. Because the plug domain appears to strongly interact with the Rhs barrel, mechanical removal of this entire domain after translocation of the cocoon into the target cell cytosol seems unlikely. Instead, we propose that only the N-terminal peptide seal of the RhsA plug is pulled out during T6SS-dependent delivery of RhsA into a susceptible bacterial cell. The seal peptide is part of the N-terminal region that is proteolytically cleaved, so we speculate that it would be more easily removed compared to the entire plug domain, which is held in place by the anchor helix that exists downstream of the N-terminal cleavage site. Penetration of the outer membrane and peptidoglycan layer as well as translocation of RhsA through the target cell inner membrane could provide the mechanical force to remove the seal peptide, creating a channel through which the unfolded toxin domain could exit. Since the plug domain resembles the constriction site in Tc toxins that effectors must pass during the initial translocation process, the same process is conceivable for the release of the C-terminal toxin domain of RhsA.

Comparison between Rhs proteins of known structure

A common feature of all Rhs proteins that have been structurally characterized to date is the cocoon structure formed by the Rhs repeats. While the Rhs cocoons from RhsA and teneurin2 are comprised of three β-helical turns of Rhs repeats, the cocoons of Tc toxins have four turns and therefore have bigger overall dimensions and an internal cavity with larger volume. Consistent with this observation, the effector domain inside Tc toxin cocoons is larger (~30 kDa) than the toxin domain of RhsA (~15 kDa). All characterized Rhs proteins contain a conserved C-terminal region. For Tc toxins and RhsA this domain functions as aspartyl autoprotease whereas in teneurins it acts as a YD-shell plug that is not cleaved (Fig 4 blue). In all instances, the C-terminal conserved region comprises 14 Rhs repeats that spiral into the inside of the cocoon and seal it at one end.

Fig 4. Structural comparison of Rhs repeat containing proteins.

Fig 4

The C-terminal autoproteolysis domain (left and middle) or YD-shell plug (right) is structurally conserved among diverse Rhs proteins (blue). RhsA and BC components of Tc toxin complexes encapsulate their toxic effector domains (red) whereas in teneurin proteins the toxin domain is appended to the outside of the Rhs barrel (red). A distinguishing feature of these Rhs proteins is the unique N-terminal plug domain for each protein family (orange). RhsA is capped by a cork-like plug domain that seals the Rhs barrel (orange). In Tc toxins, the homologous plug domain acts as constriction site and the cocoon is sealed off by a β-propeller domain (green). Teneurin proteins are capped with a non-homologous FN-plug (orange) that is stabilized by an NHL domain (green). The lower row shows schematic representations of the domain organizations.

The plug domains that close off the N-terminal end of the cocoon structures are more variable than their C-terminal counterparts (Fig 4 orange). While the barrel of teneurins is sealed with an FN-plug that is mainly held in place by hydrophilic interactions with the interior of the barrel, TcdB2 from Photorhabdus luminescens and other BC components of Tc toxins close the cocoon using a β-propeller domain that acts as gatekeeper for toxin release. RhsA uses an N-terminal plug domain, which is homologous to the domain that forms the constriction site in Tc toxins. Both TcBC and RhsA encapsule a toxic effector, whereas teneurins act as scaffolding proteins with an empty cocoon (Fig 4 red). Nevertheless, teneurins encode a C-terminal ancient toxin component that sits outside of the barrel and is inactive (ABD Tox-GHH, Fig 4 red). While RhsA contains two autoprotease sites, namely an aspartyl protease that is responsible for the cleavage of the C-terminal toxic effector and an unknown protease site that cleaves the N-terminal 304 residues of the protein, Tc toxins only contain the former site and teneurins none at all.

In conclusion, based on its unique plug domain and its fusion to an N-terminal PAAR domain, we propose that our RhsA structure represents the founding member of a third structural class of Rhs repeat containing proteins (Fig 4).

Architecture of the pre-firing complex

To investigate how RhsA is mounted onto VgrG1 we set out to determine the structure of the secretion competent pre-firing complex (PFC) comprising VgrG1 in complex with full-length RhsA and EagR1. We purified the complex as described previously [14] and examined it by single particle cryo-EM. The 2D class averages enabled us to unequivocally characterize the arrangement of the subunits within the complex (Fig 5A). Expectedly, both EagR1 and RhsA are located at the tip of VgrG1. Interestingly, a large fraction of PFCs contained RhsA dimers instead of monomers (S9B Fig), similar to what was observed in our analysis of RhsAΔTMD alone. This demonstrates that the loading of two RhsA molecules onto one VgrG1 is sterically possible although it is unlikely to occur in vivo given that current data indicates a single VgrG homotrimer caps the Hcp tube [36].

Fig 5. High-resolution structure of P. protegens VgrG1.

Fig 5

(A) The RhsA barrel of the assembled pre-firing complex (PFC) displays high positional flexibility relative to VgrG1. Representative cryo-EM 2-D class averages depicting flexibility are shown. Scale bar, 10 nm. (B) Cryo-EM density and (C) ribbon representation of the molecular model of the P. protegens VgrG1 trimer viewed along the long axis of the protein. Each protomer is colored differently to highlight their positions within the homotrimeric VgrG1 spike.

As is the case for the previously characterized VgrG1-EagT6-Tse6 complex from P. aeruginosa [16], T6SS effectors can adopt multiple positions relative to their cognate VgrG spike protein. Unfortunately, this conformational heterogeneity prevented us from obtaining a high-resolution 3D reconstruction of the entire complex (S1 Movie). Instead, we applied C3 symmetry during processing to determine the three-dimensional structure of P. protegens VgrG1 (Fig 5B). In applying this symmetry operator, the RhsA and EagR1 components of the complex, which do not adopt this symmetry, are averaged out during image processing. The cryo-EM map of VgrG1 reached a resolution of 3.3 Å and allowed us to build almost the complete atomic model of the protein comprising residues 8–643 (Fig 5C and Table 1). As expected, given its high sequence homology, the structure of VgrG1 from P. protegens is nearly identical (71% sequence identity, 81% sequence similarity) to our previously determined VgrG1 structure from P. aeruginosa (r.m.s.d of 1.035 between 544 pruned Cα atoms; r.m.s.d of 1.428 across the complete structure, S9B and S9C Fig) [16] even though their respective effectors, RhsA and Tse6, bear no sequence or structural similarity to one another beyond their N-terminal prePAAR and PAAR domains. Intriguingly, we identified two spherical densities in the center of the β-sheet prism of the VgrG1 trimer (S9E Fig). Since we also observed these densities previously in the VgrG1 structure from P. aeruginosa [16], we speculate that this may be a common feature of VgrG1 proteins. Based on the exclusive clustering of positively charged residues around this density and its overall size, we hypothesize that it corresponds to either a phosphate or sulfate anion, which probably helps to stabilize the core of VgrG1 given that in the absence of this anion, the presence of positively charged residues in the core of the protein would be energetically unfavorable.

Model of RhsA firing events and toxin release

Based on the collective structural and functional data presented in this work, combined with the findings of other recently published [18,34] work on T6SS-exported Rhs proteins, we propose a model for cytoplasmic delivery of RhsA and suggest a possible release mechanism for the toxin domain of the effector (Fig 6).

Fig 6. Model of T6SS-dependent delivery of RhsA into the cytoplasm of a susceptible bacterial cell.

Fig 6

(1–3) RhsA undergoes N- and C-terminal autoproteolytic processing. The prePAAR motif ‘completes’ the PAAR domain fold. The EagR1 chaperone solubilizes the two transmembrane helices of RhsA to facilitate loading onto its cognate cytoplasmic VgrG1 (via the prePAAR + PAAR domain). (4) The secretion competent RhsA effector is loaded onto the VgrG1 spike. (5) During a firing event the EagR1 chaperone is dissociated from the complex and the T6SS injects the PFC into target cells where it crosses the peptidoglycan (PG) layer and inserts into the inner membrane (IM) (5A). Alternatively, the tip of the VgrG1 spike could be directly delivered into the cytosol along with RhsA (5B). (6–8) Two different scenarios (6A or 6B,C) are proposed as possible mechanisms for toxin domain release from the cocoon into the cytosol of the target cell. Either the toxin domain alone (mechanism 6A) or the entire RhsA barrel is translocated across the inner membrane (mechanism 6B). In both cases, the seal of the cocoon is likely removed by translocation-induced pulling and the energy required for release and translocation of the toxin domain out of the Rhs cage is probably driven by its spontaneous refolding in the prey bacterium’s cytosol.

First, RhsA is expressed and autoproteolytically cleaved at defined N- and C-terminal positions. The N-terminal domain comprising the prePAAR motif, TMD region, PAAR domain and the linker to the Rhs barrel likely all simultaneously interact with the EagR1 chaperone and this complex remains associated with the RhsA cocoon. The C-terminal domain comprising the detached toxin domain is partially unfolded and remains inside the cocoon.

EagR1 then shields the transmembrane domains of RhsA from the aqueous milieu as the effector is loaded onto VgrG1 in the cytoplasm of the T6SS-containing cell resulting in a mature PFC. The exact location of T6SS effector delivery in the target cell remains unclear and may differ depending on the T6SS tail spike complex being exported [37,38]. Nonetheless, most characterized PAAR effectors exert their catalytic activity in the cytosol of the target cell, i.e. (p)ppApp synthetases, ADP-ribosyl transferases, DNases and NAD+/NADP+ hydrolases [11,35,39,40]. We propose that the RhsA-loaded VgrG1 tip is delivered to the periplasm as we have previously suggested for the Tse6 effector and that the PFC spontaneously enters the target cell inner membrane [16]. It remains unclear at which step the chaperone is stripped off; however, Coulthurst and colleagues detected a secreted T6SS Rhs effector in Serratia by mass spectrometry and did not detect its cognate Eag chaperone [41]. This finding supports a model whereby EagR1 dissociates from the spike complex during the loading event of the PFC onto an Hcp tube inside the lumen of the T6SS baseplate. But given the observation that the TMD helices are unstable without their protective chaperones [14], it is also conceivable that EagR1 is removed shortly before insertion into the membrane of the target cell. As proposed previously for Tse6, we suggest that the transmembrane helices of the TMD region spontaneously enter the inner membrane of the target cell [16].

Given the rigid structure of RhsA, we propose that the barrel remains intact during the firing and translocation events. Two different scenarios are conceivable for the release of the toxin domain from the cocoon and its delivery into the cytosol of the target cell if the VgrG spike only protrudes into the periplasm. In one scenario, translocation of the linker between the PAAR domain and the plug domain would lead to the removal of the seal peptide. This would result in the opening of a passageway through which the toxin domain could be threaded in an unfolded or partially unfolded state and subsequently translocated, with the assistance of the N-terminal transmembrane helices, into the cytosol. In this case, the RhsA barrel would remain in the periplasm but interact directly with the inner membrane of the target cell. This model has similarity to the currently proposed model for translocation of diphtheria toxin from Corynebacterium diphtheriae. In this case, two α-helical hairpins insert into the endosomal membrane and form a translocation channel through which the toxin is delivered into the cytosol of the intoxicated cell [42]. The refolding of diphtheria toxin in the target cell cytosol is thought to drive the translocation through the loosened-up membrane structure created by the two inserted transmembrane helices. Moreover, it was previously shown [18] that the two VgrG-interacting domains of the T6SS effector TseI from A. dhakensis, denoted as VIRN and VIRC, which are equivalent to the cleaved N- and C-terminal domains of RhsA, interact directly with one other even in the absence of the Rhs shell. Hence, it seems plausible that once the seal peptide is removed from RhsA, the unfolded C-terminal toxin domain will be threaded out of the barrel via interactions with its N-terminal domain.

In a second scenario, the TMD region would facilitate the translocation of the entire RhsA protein. Mechanical forces during translocation in combination with hydrophobic interactions in the membrane could lead to ‘tugging’ of the N-terminal domain and a release of the toxin domain from the cocoon. However, since the barrel is large (86 x 65 Å), its transport across the membrane is relatively unlikely. In both scenarios, the energy required for the release and translocation of the toxin domain into the target cell cytosol would be driven by spontaneous toxin refolding [43].

An alternative route would be the direct delivery of the barrel into the cytosol. This would require that the PFC not only penetrates the outer membrane, but also the inner membrane to reach the cytosol of the target cell. In this case, the cocoon would be located in the cytosol of the target cell, and the toxin domain would be released analogously to above-described scenario B. However, it is unclear what the role of the TMD would be in this alternative delivery mechanism.

Besides the proposed scenarios, other pathways for RhsA delivery and toxin release that have not been described are also conceivable. For example, periplasmic or inner membrane proteins found in the target cell could be involved in the active transport of the toxin from the periplasm into the cytosol.

Overall, this study provides detailed molecular insights into the autoproteolytic processing of Rhs effectors and its importance for toxin release inside the target cell. It not only enhances our knowledge about Rhs effector function, but also lays a foundation for a mechanistic understanding of how the T6SS machinery functions. The unique ability of the T6SS to mediate contact-dependent killing of a wide range of bacteria may enable development of novel therapeutics for selective depletion of drug-resistant bacterial pathogens.

Materials and methods

Bacterial strains and culture conditions

Pseudomonas protegens Pf-5 (S1 Table) was grown in Lysogeny Broth (LB) (10 g L-1 NaCl, 10 g L-1 tryptone, and 5 g L-1 yeast extract) at 30°C or on solid LB containing 1.5% or 3% agar. Media were supplemented with gentamicin (30 μg mL-1) and irgasan (25 μg mL -1) as needed.

Escherichia coli strains XL-1 Blue, SM10 and CodonPlus (DE3) were used for plasmid maintenance and toxicity experiments, conjugative transfer and protein overexpression, respectively (S1 Table). All E. coli strains were grown at 37°C in LB medium. Unless otherwise noted, media was supplemented with 150 μg mL-1 carbenicillin, 50 μg mL-1 kanamycin, 200 μg mL-1 trimethoprim, 15 μg mL-1 gentamicin, 0.25–1.0 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), 0.1% (w/v) rhamnose or 40 μg mL-1 X-gal.

DNA manipulation and plasmid construction

All primers used in this study were synthesized by Integrated DNA Technologies (IDT). Molecular biology reagents (Phusion polymerase, restriction enzymes and T4 DNA ligase) were obtained from New England Biolabs (NEB). Sanger sequencing was performed by Genewiz Incorporated.

Heterologous expression plasmids: pETDuet-1, pET29b and pSCrhaB2-CV. Splicing by overlap-extension PCR was used to make mutant constructs. Standard restriction enzyme-based cloning procedures were subsequently used to ligate wild-type or mutant PCR products into the plasmid of interest.

Generation of P. protegens mutants

In-frame chromosomal deletion mutants in P. protegens were made using the pEXG2 plasmid as described previously for Pseudomonas aeruginosa [44]. Briefly, ~500 bp upstream and downstream of target gene were amplified by standard PCR and spliced together by overlap-extension PCR. The resulting DNA fragment was ligated into the pEXG2 allelic exchange vector using standard cloning procedures (S2 Table). Deletion constructs were transformed into E. coli SM10 and subsequently introduced into P. protegens via conjugal transfer. Merodiploids were directly plated on LB (lacking NaCl) containing 5% (w/v) sucrose for sacB-based counter-selection. Deletions were confirmed by colony PCR in strains that were resistant to sucrose, but sensitive to gentamicin. Chromosomal point mutations or epitope tags were constructed similarly with the constructs harboring the mutation or tag cloned into pEXG2. Sucrose-resistant and gentamicin-sensitive colonies were confirmed to have the mutations of interest by Sanger sequencing of appropriate PCR amplicons.

Pseudomonas growth competition assays

Recipient P. protegens strains contained a ΔpppA mutation to stimulate T6SS effector secretion and induce a ‘counterattack’ from P. protegens donor strains [45]. Recipient strains were also marked with a tetracycline-resistant, lacZ-expression cassette at a neutral phage site (attB) to differentiate from unlabeled donor strains.

Stationary-phase overnight cultures of P. protegens donors and recipients were mixed in a 1:1 (v/v) ratio and relative abundance of donor:recipient was determined by plating part of the competition mixture on LB plates with 40 μg mL-1 X-gal. Ten microlitres of each competition mixture was then spotted on a 0.45 μm nitrocellulose membrane that was overlaid on a 3% LB agar plate and incubated face up at 30°C. Competition spots were harvested after 20–25 hours by resuspending in LB and counting CFU by plating on LB agar with 40 μg mL-1 X-gal. The final ratio of donor:recipient colony forming units were then normalized to the initial ratios of donor and recipient strains and reported as the log10 of the competitive index.

Toxicity assays

Wild-type RhsA and the various RhsA truncations and site-specific mutants used in this study were cloned into the rhamnose-inducible pSCrhaB2-CV vector [46]. RhsI was cloned into the IPTG-inducible vector pPSV39 [12]. The various RhsA expressing pSCrhaB2-CV plasmids were co-transformed into E. coli XL-1 Blue with pPSV39::rhsI. Stationary-phase overnight cultures containing these plasmids were serially diluted 10−6 in 10-fold increments and each dilution was spotted onto LB agar plates containing 0.1% (w/v) L-rhamnose, 500 μM IPTG, trimethoprim 250 μg mL-1 and 15 μg mL-1 gentamicin. Photographs were taken after overnight growth at 37°C.

Protein expression and purification

Wild-type RhsA, its N-terminal (C538A, D322A, H530A, D318-320A) and C-terminal autoproteolysis mutants (D1346A, D1364N) were cloned into MCS-1 of pETDuet-1 and co-expressed with RhsI, which was cloned into MCS2. Plasmids were co-transformed into E. coli BL21 Codon Plus alongside a pET29b vector expressing EagR1.

Purification of RhsAΔTMD and VgrG1 for cryo-EM

RhsAΔTMD was co-expressed with RhsI using pETDuet-1 (see S2 Table for details). VgrG1 was expressed in isolation using pET29b. Plasmids were individually expressed in E. coli BL21 Codon Plus. Strains harboring pETDuet-1 expressing RhsAΔTMD-RhsI or pET29b expressing VgrG1 were inoculated in separate flasks containing 100 mL LB with selection and incubated overnight in a shaking incubator at 37°C. Following 14-18hr incubation, the culture was subinoculated (1/50 dilution) into four flasks each with 1 litre of LB and appropriate antibiotic selection. Cultures were initially incubated at 37°C until the culture reached an OD of ~0.3. The incubator was subsequently cooled to 18°C and each culture induced with 1 mM IPTG upon reaching an OD of 0.6–0.7. Cultures were harvested by centrifugation at 9,800 g for 10 minutes. Pellets were resuspended in 30 mL lysis buffer (50 mM Tris-HCl, 300 mM NaCl, 10 mM imidazole) and lysed by sonication (6 x 30 second pulses, amplitude 30%) and then spun at 39,000 g. Cleared lysates were applied to a Ni-NTA gravity flow column equilibrated using lysis buffer. The column was washed with the lysis buffer three times and the samples were eluted in 3 mL of elution buffer (lysis buffer with 400 mM imidazole). The samples were applied to a HiLoad 16/600 Superdex 200 column equilibrated in 20 mM Tris-HCl pH 8.0 150 mM NaCl and collected in the same buffer. The sample was reinjected into a Superose 6 5/150 column using the same buffer for EM analysis and de novo protein sequencing.

Western blot analyses

Western blot analyses were performed using rabbit anti-RhsA (diluted 1:5,000, Genscript, custom polyclonal [14]), rabbit anti-FLAG (diluted 1:5,000, Sigma), rabbit anti-VSV-G (diluted 1:5,000; Sigma) and mouse anti-His6 (diluted 1:5,000, Genscript) and detected with anti-rabbit or anti-mouse horseradish peroxidase-conjugated secondary antibodies (diluted 1:5,000; Sigma). Development of western blots was completed using chemiluminescent substrate (Clarity Max, Bio-Rad) and imaged with the ChemiDoc Imaging System (Bio-Rad).

De novo protein sequencing via LC-MS/MS

RhsAΔTMD was purified as described above. A concentrated sample was applied onto an SDS-PAGE. The band corresponding to the N- and C-terminally autoproteolyzed Rhscage was excised from the gel and analysed by LC-MS/MS at the Proteome Factory AG company. The original data is provided as supplementary data (S1 Dataset).

Negative stain electron microscopy

Four microliters of sample at a concentration of 0.005 mg/ml were applied to freshly glow-discharged carbon-coated copper grids. After 90s incubation time, excess sample was blotted away with Whatman No. 4, then washed twice with four microliters purification buffer and once with 0.75% (w/v) uranyl formate. A second batch of staining solution was incubated on the grid for 90s before excess was again blotted away. Grids were air-dried and imaged on a JEOL JEM-1400 microscope, equipped with a LaB6 cathode and 4k × 4k CMOS detector F416 (TVIPS), operating at 120 kV.

Sample vitrification and data collection

Three microliters of the EagR1-RhsA-VgrG1 complex, at a concentration of 0.1 mg/ml, were applied to a freshly glow-discharged holey carbon grid (QF 2/1 200-mesh). The grid was blotted for 3s (blot force -5, drain time 0.5 s, 8°C, 100% humidity) and immediately plunged into nitrogen cooled liquid ethane using a Vitrobot Mark IV (Thermo Fisher Scientific). Data collection was performed on a CS-corrected Titan Krios (Thermo Fisher Scientific) operating at 300 kV in an automated fashion using EPU (Thermo Fisher Scientific). Movies were recorded on a Falcon 3 detector in linear mode at a nominal magnification of 59,000x with a calibrated pixel size of 1.1 Å/pixel. Image stacks were acquired in a defocus range from -1.2 to -2.2 μm with an accumulated dose of 90 e2 fractionated over 40 frames with a total exposure time of 1.5 s.

For RhsAΔTMD, three microliters of sample, at a concentration of 4 mg/ml, were applied to a freshly glow-discharged holey carbon grid (QF 1.2/1.3 200-mesh). The grid was blotted for 3s (blot force -5, drain time 0.5 s, 8°C, 100% humidity) and immediately plunged into liquid ethane using a Vitrobot Mark IV (Thermo Fisher Scientific). The grid was transferred to a Titan Krios (Thermo Fisher Scientific) operating at 300 kV equipped with a GIF BioQuantum energy filter (Gatan), set to a slit width of 20 eV, and K3 Summit Detector (Gatan). Movies were recorded in counting mode at a nominal magnification of 105,000x with a calibrated pixel size of 0.91 Å/pixel in an automated fashion using EPU (Thermo Fisher Scientific). Image stacks were acquired in a defocus range from -0.8 to -2.2 μm with an accumulated dose of 61 e2 fractionated over 20 frames with a total exposure time of 2 s.

Both datasets were monitored live with TranSPHIRE [47] to evaluate i.e. the defocus range and astigmatism. Pre-processing was performed on-the-fly in TranSPHIRE including drift-correction and dose-weighting with MotionCor2 [48], CTF estimation on dose-weighted micrographs with CTFFIND4 [49] and picking using the general model of crYOLO [50].

Cryo-EM image processing

After preprocessing in TranSPHIRE all processing steps were carried out in the SPHIRE [51] software package unless otherwise stated. Images with a resolution limit less than 6 Å were unselected using the graphical CTF assessment tool in SPHIRE for both datasets.

In case of the PFC, particles were extracted with box size of 408 x 408 pixels from 1250 good micrographs. Reference-free 2D classification and cleaning of the dataset was performed with the iterative stable alignment and clustering approach ISAC [52] implemented in SPHIRE. ISAC was performed at pixel size of 6.29 Å/pix. Using the Beautifier tool, the original pixel size was restored creating sharpened 2D class averages showing high-resolution details. A subset of particles showing clear high-resolution details were selected for structure refinement. 3D refinement was performed in MERIDIEN imposing C3 symmetry with a 25 Å lowpass-filtered reference of our previously determined VgrG1 structure (EMD-0136). The two half-maps were combined with the PostRefiner tool in SPHIRE using a soft mask and automatic estimation of B-factors. Details of the processing workflow are shown in S9 Fig.

For RhsAΔTMD, particles were extracted from 13,090 good micrographs with a final box size of 288 x 288 pixels. Particles were subjected to ISAC which was performed at pixel size of 3.3 Å/pix. A subset of particles showing high-resolution features were selected from beautified class averages. An initial reference for refinement was generated from the beautified averages using RVPER. All refinements and classifications were performed with implied C2 symmetry. Subsequent 3D refinement of the good particles with MERIDIEN yielded a map of overall 3.6 Å resolution but showed clear resolution anisotropy in the peripheries of the barrels. We imported the particle stack into RELION 3.1.0 [53] with projection parameters obtained from MERIDIEN. Particles were classified into 4 classes without image alignment (T = 4, C2 symmetry, soft mask) using the map from MERIDIEN as reference low-pass filtered to 30 Å. The particles belonging to the class displaying the highest resolution were selected for another round of MERIDIEN after removal of duplicated particles (minimum inter-particle distance threshold 100 Å). Particles were further CTF-refined and polished in Relion. The final refinement was performed with MERIDIEN. The final map was evaluated using the 3D FSC tool [54]. Map for Fig 1 and was postprocessed with the DeepEMhancer [55] using the high-resolution model. Local resolution was estimated with a normal postprocessed map in SPHIRE. Details of the processing workflow are shown in S1 Fig.

Model building, refinement and validation

The previously obtained VgrG1 structure from P. aeruginosa (PDB ID: 6H3L) was docked into the map as rigid body in UCSF Chimera [56]. The P. protegens VgrG1 sequence was manually adjusted in Coot [57] and iteratively refined in Phenix [58] and ISOLDE [59]. Model validity was assessed in Phenix with MolProbity [60]. Final model statistics are given in Table 1.

For RhsAΔTMD, initial backbone traces were identified with automated model building software Buccaneer [61]. The model was manually adjusted to completion in Coot [57] using both the DeepEMHanced and a normal postprocessed map to exclude any bias. Stabilized β-strands of the toxin domain were identified via secondary structure prediction and manually placed inside the densities. The single interpretable α-helix was not predicted by secondary structure predictions. Instead, we manually check the rest of the sequence to determine the sequence register. We placed residues 289–302 in this density guided by AlphaFold [62] predictions. This was moreover guided by the matched hydrophobicity towards the interacting Rhs repeats. To identify residues corresponding to the linker density which complements the plug domain, we searched in the vicinity of the helix sequence for residues encoding bulky side chains. F271 served as anchor point to build residues 268–275 guided by AlphaFold [62] predictions.

Iterative refinement of the model in Phenix [58] and ISOLDE [59] was performed until convergence. Model validity was assessed in Phenix with MolProbity [60]. Final model statistics are given in Table 1.

Figures were prepared in Chimera X [63]. Multiple sequence alignments and secondary structure predictions were calculated using the MPI Bioinformatics toolkit [64,65] and visualized for creation of figures in Jalview [66].

The cryo-EM maps of VgrG1 and RhsA have been deposited in the Electron Microscopy Data Bank (EMDB) under the accession codes of EMD-13843 and EMD-13867, respectively. The refined models for VgrG1 and RhsA were uploaded in the PDB and the entries have the IDs 7Q5P and 7Q97, respectively.

Supporting information

S1 Fig. Cryo-EM processing workflow used to obtain the structure of RhsAΔTMD.

(A) Purification of RhsAΔTMD via size-exclusion chromatography using a Superose 6 5/150 increase column. Molecular weight standards are indicated at their respective elution volumes. The grey bar denotes pooled and concentrated fractions used for cryo-EM analysis. The same material was analyzed for purity via semi-denaturing SDS-PAGE imaged with a stain-free filter. (B) Representative cryo-EM micrograph of RhsAΔTMD used for structural determination. Scale bar EM micrograph, 100 nm. Particles were picked with the general model of crYOLO. The rest of the processing workflow is indicated and summarized in the Materials and Methods section. Scale bar 2D class averages, 10 nm. Used software packages are highlighted. Orange font depict steps carried out in Relion. The final map was calculated using MERIDIEN and postprocessed with DeepEMhancer. (C) Angular distribution plot of the final reconstruction. (D) Local resolution estimates visualized on a map postprocessed in SPHIRE. (E) Fourier shell correlation plot calculated from two independently processed maps. Resolution estimation is reported at the gold standard cutoff of 0.143. (F) Resolution anisotropy was assessed with the 3DFSC online server tool. (G) Selected regions of the map are shown as transparent surface with the built atomic models as stick representations.

(TIF)

S2 Fig. Structural analysis of the dimer interface of RhsA.

(A) Close up view of the dimer interface of the two RhsA molecules at the central symmetry axis. Potential candidate residues engaging in stabilizing interactions are labelled and shown in stick representation. (B) Surface properties of the dimer interface and the periphery of RhsA. The surface of the interface is colored according to its Coulomb potential indicating positively (red, -20) and negatively (blue, +20) charged areas. The second representation shows the same interface but colored according to hydrophobicity. Ochre indicates hydrophobic and white indicates hydrophilic regions. The area facing the outer peripheries of both barrels shows that these regions would electrostatically repel each other and explain why only two barrels can interact at the same time.

(TIF)

S3 Fig. Characterization of the C-terminal autoproteolysis site of RhsA.

(A) Multiple sequence alignment of the C-terminal cleavage site. The cleavage site is indicated by the black arrow. Critical residues are highlighted by the residue numbering. Coloring is according to the ClustalW color code. (B) In E. coli toxicity assays show reduced toxicity of RhsAΔTMD harboring mutations of the catalytic aspartates D1324N and D1346N, respectively. Toxicity could by reversed by overexpression of the immune protein RhsI. The lower panel represents the same toxicity assay but with lower RhsA expression levels due to lower inducer concentration (L-rhamnose).

(TIF)

S4 Fig. Local environment of the ordered toxin fragments inside the Rhs cocoon.

Interaction of three β-strands belonging to the toxin domain of RhsA with the Rhs barrel. The toxin fragments are stabilized by the interaction with hydrophobic and hydrophilic surfaces inside the Rhs barrel. The molecular surface is colored according to hydrophobicity with ochre and white indicating hydrophobic and hydrophilic regions, respectively. The electrostatic representation is colored according to Coulomb potential, which depicts positively (red, -20) and negatively (blue, +20) charged areas.

(TIF)

S5 Fig. Characterization of the N-terminal autoproteolysis site of RhsA.

(A) The N-terminal cleavage site was identified by protein sequencing. The band containing the Rhscage was excised and analyzed by de novo protein sequencing using LC-MS/MS. (B) Western blot analysis of wild-type or a N-terminal cleavage resistant mutant (H304A/P305A) confirming the location of the cleavage site at P305. (C) Multiple sequence alignment of the N-terminal cleavage site. The cleavage site is indicated by a black arrow. Coloring is according to the ClustalW color code. (D) Sequence alignment of the T6SS class I prePAAR effectors highlighting the N-terminal cleavage site. Residue conservation is depicted as Weblogo. The Weblogo represents residue conservation. (E) Cartoon representation of the N-terminal cleavage site in RhsA. Residues A312 and K313 as well as conserved and potential catalytically active residues are show in stick representation. Residues A312 and K313 correspond to the catalytically active glutamates in TseI [18]. (F) Hypothesized cysteine protease motif which is near the N-terminal cleavage site P305. (G) Multiple sequence alignment highlighting the conservation of the hypothesized cysteine protease motif among class I prePAAR effectors. The Weblogo represents residue conservation. (H) Western blot analysis of potential residues involved in N-terminal cleavage and generation of the cleavage product RhsAN. Impaired cleavage was assessed by appearance of the full-length RhsA chain which is a mixture of both species, the C-terminally cleaved fragment (-CT) and the C-terminally uncleaved fragment (+CT). RhsA was coexpressed with its cognate chaperone EagR1. The blot was performed against N-terminal His6-tagged proteins (α-His). (I) Western blot analysis to examine the potential involvement of RhsA’s C-terminal toxin domain in the autoproteolysis of its N-terminal region. An RhsA truncation lacking the C-terminal toxin domain (RhsAΔtox, residues 1–1323) was expressed and examined for N-terminal cleavage using antibodies that recognize its N-terminus (α-FLAG) or its Rhs cocoon (α-RhsA).

(TIF)

S6 Fig. Hydrophilic interactions of the plug domain with the Rhs barrel.

(A) Only a few hydrophilic interactions stabilize the plug domain. Residues participating in hydrogen bonds are labeled and shown in stick representation. The cork and the seal are colored in orange whereas the Rhs repeats is colored in beige. (B) The barrel would not be closed without the observed density corresponding to the seal. The model for the seal was manually removed to visualize the opening though which toxin is threaded into the target cell after removal of the seal and the anchor helix.

(TIF)

S7 Fig. Stabilization of the N-terminal seal and anchor helix of RhsA.

(A-B) A small density, corresponding to seal (residues K268-V275) of RhsA enters the barrel from the top (mesh). This results in a complete sealing of the cocoon. (C–E) The seal leads further down into an amphipathic helix which strongly interacts with the inner surface of the cocoon and thus serves as an anchor point for the N-terminal domain. The amphipathic helix is stabilized by hydrophobic interactions with Rhs repeats.

(TIF)

S8 Fig. Comparison of Rhs repeat containing proteins of known structure.

(A) Comparison of the plug domains of RhsA (orange) with YenBC (PDB ID: 4IGL), TcdB2-TccC3 (PDB ID: 6H6G) and Ten2CT (PDB ID: 6FB3). (B) Sequence alignment of the plug domain of RhsA with the sequences of the homologous domains found in TcdB2-TccC3 (top) and YenBC (bottom) are shown. Residues are colored according to the ClustalW color code. (C) Structural overlay of RhsA with YenBC (left) and Ten2CT (right).

(TIF)

S9 Fig. Cryo-EM of the PFC.

(A) Representative negative stain micrograph and 2D class averages of the intact PFC consisting of VgrG1, RhsA and EagR1. Scale bar micrograph, 100 nm. Scale bar 2D class averages, 10 nm. (B) Cryo-EM micrograph of the PFC and image processing workflow. Particles were picked with the general model of crYOLO and classified with ISAC. Refinement in MERIDIEN led to a reconstruction of 3.3 Å (FSC = 0.143 criterion). The final reconstruction was either colored individually for each protomer or according to local resolution. Fourier shell correlation was plotted according to two independent refined maps. Dashed line indicates the gold standard FSC criterion of 0.143. Scale bar micrograph, 100 nm. Scale bar 2D class averages, 10 nm. (C) Overlay of VgrG1 from P. protegens (green) with VgrG1 from P. aeruginosa (blue, PDB ID: 6H3N). (D) Map quality of selected parts of the structure (transparent surface) with built atomic models (cartoon representation). (E) Potential ion binding site in the middle part of the β-prism of P. protegens VgrG1. Sulfate ions were modelled into the spherical densities. Coordinating residues are displayed in stick representation.

(TIF)

S1 Table. Bacterial strains used in this study.

(DOCX)

S2 Table. Plasmids used in this study.

(DOCX)

S1 Movie. Flexibility of the VgrG1-RhsA-EagR1 complex.

This video highlights the positional flexibility of RhsA relative to the VgrG1 spike protein.

(MP4)

S1 Dataset. Dataset of de novo protein sequencing of RhsA.

(ZIP)

Acknowledgments

We thank D. Prumbaum and O. Hofnagel for assistance in electron microscopy data collection and maintaining the EM facility.

Data Availability

The cryo-EM maps of VgrG1 and RhsA have been deposited in the Electron Microscopy Data Bank (EMDB) under the accession codes of EMD-13843 and EMD-13867, respectively. The refined models for VgrG1 and RhsA were uploaded in the PDB and the entries have the IDs 7Q5P and 7Q97, respectively. The original data of the de novo protein sequencing is available inprovided as supplementary data (the S1 Dataset).

Funding Statement

This work was supported by the Max Planck Society (to S.R.) and a Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (RGPIN-2017–05350 to J.C.W.). J.C.W. is the Canada Research Chair in Molecular Microbiology and holds an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Mougous JD, Cuff ME, Raunser S, Shen A, Zhou M, Gifford CA, et al. A virulence locus of Pseudomonas aeruginosa encodes a protein secretion apparatus. Science (80-). 2006;312: 1526–1530. doi: 10.1126/science.1128393 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Pukatzki S, Ma AT, Sturtevant D, Krastins B, Sarracino D, Nelson WC, et al. Identification of a conserved bacterial protein secretion system in Vibrio cholerae using the Dictyostelium host model system. Proc Natl Acad Sci U S A. 2006;103: 1528–1533. doi: 10.1073/pnas.0510322103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Russell AB, Hood RD, Bui NK, Leroux M, Vollmer W, Mougous JD. Type VI secretion delivers bacteriolytic effectors to target cells. Nature. 2011;475: 343–349. doi: 10.1038/nature10244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chang Y, Rettberg LA, Ortega DR, Jensen GJ. In vivo structures of an intact type VI secretion system revealed by electron cryotomography. EMBO Rep. 2017;18: 1090–1099. doi: 10.15252/embr.201744072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Silverman JM, Brunet YR, Cascales E, Mougous JD. Structure and regulation of the type VI secretion system. Annu Rev Microbiol. 2012;66: 453–472. doi: 10.1146/annurev-micro-121809-151619 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Cianfanelli FR, Monlezun L, Coulthurst SJ. Aim, Load, Fire: The Type VI Secretion System, a Bacterial Nanoweapon. Trends Microbiol. 2016;24: 51–62. doi: 10.1016/j.tim.2015.10.005 [DOI] [PubMed] [Google Scholar]
  • 7.Ho BT, Dong TG, Mekalanos JJ. A view to a kill: The bacterial type VI secretion system. Cell Host Microbe. 2014;15: 9–21. doi: 10.1016/j.chom.2013.11.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Shneider MM, Buth SA, Ho BT, Basler M, Mekalanos JJ, Leiman PG. PAAR-repeat proteins sharpen and diversify the type VI secretion system spike. Nature. 2013;500: 350–353. doi: 10.1038/nature12453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lossi NS, Manoli E, Förster A, Dajani R, Pape T, Freemont P, et al. The HsiB1C1 (TssB-TssC) complex of the Pseudomonas aeruginosa type VI secretion system forms a bacteriophage tail sheathlike structure. J Biol Chem. 2013;288: 7536–7548. doi: 10.1074/jbc.M112.439273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.English G, Trunk K, Rao VA, Srikannathasan V, Hunter WN, Coulthurst SJ. New secreted toxins and immunity proteins encoded within the type VI secretion system gene cluster of Serratia marcescens. Mol Microbiol. 2012;86: 921–936. doi: 10.1111/mmi.12028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ting SY, Bosch DE, Mangiameli SM, Radey MC, Huang S, Park YJ, et al. Bifunctional Immunity Proteins Protect Bacteria against FtsZ-Targeting ADP-Ribosylating Toxins. Cell. 2018;175: 1380–1392.e14. doi: 10.1016/j.cell.2018.09.037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Silverman JM, Agnello DM, Zheng H, Andrews BT, Li M, Catalano CE, et al. Haemolysin Coregulated Protein Is an Exported Receptor and Chaperone of Type VI Secretion Substrates. Mol Cell. 2013;51: 584–593. doi: 10.1016/j.molcel.2013.07.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Flaugnatti N, Le TTH, Canaan S, Aschtgen MS, Nguyen VS, Blangy S, et al. A phospholipase A1 antibacterial Type VI secretion effector interacts directly with the C-terminal domain of the VgrG spike protein for delivery. Mol Microbiol. 2016;99: 1099–1118. doi: 10.1111/mmi.13292 [DOI] [PubMed] [Google Scholar]
  • 14.Ahmad S, Tsang KK, Sachar K, Quentin D, Tashin TM, Bullen NP, et al. Structural basis for effector transmembrane domain recognition by type VI secretion system chaperones. Elife. 2020;9: 1–29. doi: 10.7554/eLife.62816 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Whitney JC, Quentin D, Sawai S, LeRoux M, Harding BN, Ledvina HE, et al. An Interbacterial NAD(P)+ Glycohydrolase Toxin Requires Elongation Factor Tu for Delivery to Target Cells. Cell. 2015;163: 607–619. doi: 10.1016/j.cell.2015.09.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Quentin D, Ahmad S, Shanthamoorthy P, Mougous JD, Whitney JC, Raunser S. Mechanism of loading and translocation of type VI secretion system effector Tse6. Nat Microbiol. 2018;3: 1142–1152. doi: 10.1038/s41564-018-0238-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lin RJ, Capage M, Hill CW. A repetitive DNA sequence, rhs, responsible for duplications within the Escherichia coli K-12 chromosome. J Mol Biol. 1984;177: 1–18. doi: 10.1016/0022-2836(84)90054-8 [DOI] [PubMed] [Google Scholar]
  • 18.Pei TT, Li H, Liang X, Wang ZH, Liu G, Wu LL, et al. Intramolecular chaperone-mediated secretion of an Rhs effector toxin by a type VI secretion system. Nat Commun. 2020;11. doi: 10.1038/s41467-020-15774-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Jurėnas D, Journet L. Activity, delivery, and diversity of Type VI secretion effectors. Mol Microbiol. 2021;115: 383–394. doi: 10.1111/mmi.14648 [DOI] [PubMed] [Google Scholar]
  • 20.Jackson AP, Thomas GH, Parkhill J, Thomson NR. Evolutionary diversification of an ancient gene family (rhs) through C-terminal displacement. BMC Genomics. 2009;10: 1–16. doi: 10.1186/1471-2164-10-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Tucker RP, Beckmann J, Leachman NT, Schöler J, Chiquet-Ehrismann R. Phylogenetic analysis of the teneurins: Conserved features and premetazoan ancestry. Mol Biol Evol. 2012;29: 1019–1029. doi: 10.1093/molbev/msr271 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Minet AD, Rubin BP, Tucker RP, Baumgartner S, Chiquet-Ehrismann R. Teneurin-1, a vertebrate homologue of the Drosophila pair-rule gene ten-m, is a neuronal protein with a novel type of heparin-binding domain. J Cell Sci. 1999;112: 2019–2032. doi: 10.1242/jcs.112.12.2019 [DOI] [PubMed] [Google Scholar]
  • 23.Hong W, Mosca TJ, Luo L. Teneurins instruct synaptic partner matching in an olfactory map. Nature. 2012;484: 201–207. doi: 10.1038/nature10926 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Mosca TJ, Hong W, Dani VS, Favaloro V, Luo L. Trans-synaptic Teneurin signalling in neuromuscular synapse organization and target choice. Nature. 2012;484: 237–241. doi: 10.1038/nature10923 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bagutti C, Forro G, Ferralli J, Rubin B, Chiquet-Ehrismann R. The intracellular domain of teneurin-2 has a nuclear function and represses zic-1-mediated transcription. J Cell Sci. 2003;116: 2957–2966. doi: 10.1242/jcs.00603 [DOI] [PubMed] [Google Scholar]
  • 26.Meusch D, Gatsogiannis C, Efremov RG, Lang AE, Hofnagel O, Vetter IR, et al. Mechanism of Tc toxin action revealed in molecular detail. Nature. 2014;508: 61–65. doi: 10.1038/nature13015 [DOI] [PubMed] [Google Scholar]
  • 27.Busby JN, Panjikar S, Landsberg MJ, Hurst MRH, Lott JS. The BC component of ABC toxins is an RHS-repeat-containing protein encapsulation device. Nature. 2013;501: 547–550. doi: 10.1038/nature12465 [DOI] [PubMed] [Google Scholar]
  • 28.Jackson VA, Meijer DH, Carrasquero M, Van Bezouwen LS, Lowe ED, Kleanthous C, et al. Structures of Teneurin adhesion receptors reveal an ancient fold for cell-cell interaction. Nat Commun. 2018;9: 1–9. doi: 10.1038/s41467-017-02088-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.del Toro D, Carrasquero-Ordaz MA, Chu A, Ruff T, Shahin M, Jackson VA, et al. Structural Basis of Teneurin-Latrophilin Interaction in Repulsive Guidance of Migrating Neurons. Cell. 2020;180: 323–339.e19. doi: 10.1016/j.cell.2019.12.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Lovejoy DA, Chawaf A Al, Cadinouche MZA. Teneurin C-terminal associated peptides: An enigmatic family of neuropeptides with structural similarity to the corticotropin-releasing factor and calcitonin families of peptides. Gen Comp Endocrinol. 2006;148: 299–305. doi: 10.1016/j.ygcen.2006.01.012 [DOI] [PubMed] [Google Scholar]
  • 31.Lang AE, Schmidt G, Schlosser A, Hey TD, Larrinua IM, Sheets JJ, et al. Photorhabdus luminescens ToxinsADP-Ribosylate Actin and RhoA to ForceActin Clustering. Science (80-). 2010;327: 1139–1143. doi: 10.1126/science.1184557 [DOI] [PubMed] [Google Scholar]
  • 32.Gatsogiannis C, Merino F, Roderer D, Balchin D, Schubert E, Kuhlee A, et al. Tc toxin activation requires unfolding and refolding of a β-propeller. Nature. 2018;563: 209–233. doi: 10.1038/s41586-018-0556-6 [DOI] [PubMed] [Google Scholar]
  • 33.Gatsogiannis C, Lang AE, Meusch D, Pfaumann V, Hofnagel O, Benz R, et al. A syringe-like injection mechanism in Photorhabdus luminescens toxins. Nature. 2013;495: 520–523. doi: 10.1038/nature11987 [DOI] [PubMed] [Google Scholar]
  • 34.Donato SL, Beck CM, Garza-Sánchez F, Jensen SJ, Ruhe ZC, Cunningham DA, et al. The β-encapsulation cage of rearrangement hotspot (Rhs) effectors is required for type VI secretion. Proc Natl Acad Sci U S A. 2020;117: 33540–33548. doi: 10.1073/pnas.1919350117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Tang JY, Bullen NP, Ahmad S, Whitney JC. Diverse NADase effector families mediate interbacterial antagonism via the type VI secretion system. J Biol Chem. 2018;293: 1504–1514. doi: 10.1074/jbc.RA117.000178 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Renault MG, Zamarreno Beas J, Douzi B, Chabalier M, Zoued A, Brunet YR, et al. The gp27-like Hub of VgrG Serves as Adaptor to Promote Hcp Tube Assembly. J Mol Biol. 2018;430: 3143–3156. doi: 10.1016/j.jmb.2018.07.018 [DOI] [PubMed] [Google Scholar]
  • 37.Ho BT, Fu Y, Dong TG, Mekalanos JJ. Vibrio cholerae type 6 secretion system effector trafficking in target bacterial cells. Proc Natl Acad Sci U S A. 2017;114: 9427–9432. doi: 10.1073/pnas.1711219114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Vettiger A, Basler M. Type VI Secretion System Substrates Are Transferred and Reused among Sister Cells. Cell. 2016;167: 99–110.e12. doi: 10.1016/j.cell.2016.08.023 [DOI] [PubMed] [Google Scholar]
  • 39.Ahmad S, Wang B, Walker MD, Tran HKR, Stogios PJ, Savchenko A, et al. An interbacterial toxin inhibits target cell growth by synthesizing (p)ppApp. Nature. 2019;575: 674–678. doi: 10.1038/s41586-019-1735-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys A V., Raguram A, et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020;583: 631–637. doi: 10.1038/s41586-020-2477-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Cianfanelli FR, Alcoforado Diniz J, Guo M, De Cesare V, Trost M, Coulthurst SJ. VgrG and PAAR Proteins Define Distinct Versions of a Functional Type VI Secretion System. PLoS Pathog. 2016;12: 1–27. doi: 10.1371/journal.ppat.1005735 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Murphy JR. Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process. Toxins. 2011. pp. 294–308. doi: 10.3390/toxins3030294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Roderer D, Schubert E, Sitsel O, Raunser S. Towards the application of Tc toxins as a universal protein translocation system. Nat Commun. 2019;10: 1–11. doi: 10.1038/s41467-018-07882-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Hmelo LR, Borlee BR, Almblad H, Love ME, Randall TE, Tseng BS, et al. Precision-engineering the Pseudomonas aeruginosa genome with two-step allelic exchange. Nat Protoc. 2015;10: 1820–1841. doi: 10.1038/nprot.2015.115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Basler M, Ho BT, Mekalanos JJ. Tit-for-tat: Type VI secretion system counterattack during bacterial cell-cell interactions. Cell. 2013;152: 884–894. doi: 10.1016/j.cell.2013.01.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Cardona ST, Valvano MA. An expression vector containing a rhamnose-inducible promoter provides tightly regulated gene expression in Burkholderia cenocepacia. Plasmid. 2005;54: 219–228. doi: 10.1016/j.plasmid.2005.03.004 [DOI] [PubMed] [Google Scholar]
  • 47.Stabrin M, Schoenfeld F, Wagner T, Pospich S, Gatsogiannis C, Raunser S. TranSPHIRE: automated and feedback-optimized on-the-fly processing for cryo-EM. Nat Commun. 2020;11: 1–14. doi: 10.1038/s41467-019-13993-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Zheng SQ, Palovcak E, Armache JP, Verba KA, Cheng Y, Agard DA. MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods. 2017;14: 331–332. doi: 10.1038/nmeth.4193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Rohou A, Grigorieff N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015;192: 216–221. doi: 10.1016/j.jsb.2015.08.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Wagner T, Merino F, Stabrin M, Moriya T, Antoni C, Apelbaum A, et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. Commun Biol. 2019;2: 1–13. doi: 10.1038/s42003-018-0242-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Moriya T, Saur M, Stabrin M, Merino F, Voicu H, Huang Z, et al. High-resolution single particle analysis from electron cryo-microscopy images using SPHIRE. J Vis Exp. 2017;2017: 1–11. doi: 10.3791/55448 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Yang Z, Fang J, Chittuluru J, Asturias FJ, Penczek PA. Iterative stable alignment and clustering of 2D transmission electron microscope images. Structure. 2012;20: 237–247. doi: 10.1016/j.str.2011.12.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Zivanov J, Nakane T, Forsberg BO, Kimanius D, Hagen WJH, Lindahl E, et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife. 2018;7: 1–22. doi: 10.7554/eLife.42166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Zi Tan Y, Baldwin PR, Davis JH, Williamson JR, Potter CS, Carragher B, et al. Addressing preferred specimen orientation in single-particle cryo-EMthrough tilting. Nat Methods. 2017;14: 793–796. doi: 10.1038/nmeth.4347 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Sanchez-Garcia R, Gomez-Blanco J, Cuervo A, Carazo J, Sorzano C, Vargas J. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun Biol. 2020; 1–8. doi: 10.1038/s42003-019-0734-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—A visualization system for exploratory research and analysis. J Comput Chem. 2004;25: 1605–1612. doi: 10.1002/jcc.20084 [DOI] [PubMed] [Google Scholar]
  • 57.Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr Sect D Biol Crystallogr. 2010;66: 486–501. doi: 10.1107/S0907444910007493 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Adams PD, Afonine P V., Bunkóczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr Sect D Biol Crystallogr. 2010;66: 213–221. doi: 10.1107/S0907444909052925 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Croll TI. ISOLDE: A physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr Sect D Struct Biol. 2018;74: 519–530. doi: 10.1107/S2059798318002425 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, et al. MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 2018;27: 293–315. doi: 10.1002/pro.3330 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Cowtan K. The Buccaneer software for automated model building. 1. Tracing protein chains. Acta Crystallogr Sect D Biol Crystallogr. 2006;62: 1002–1011. doi: 10.1107/S0907444906022116 [DOI] [PubMed] [Google Scholar]
  • 62.Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596: 583–589. doi: 10.1038/s41586-021-03819-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2021;30: 70–82. doi: 10.1002/pro.3943 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Zimmermann L, Stephens A, Nam SZ, Rau D, Kübler J, Lozajic M, et al. A Completely Reimplemented MPI Bioinformatics Toolkit with a New HHpred Server at its Core. J Mol Biol. 2018;430: 2237–2243. doi: 10.1016/j.jmb.2017.12.007 [DOI] [PubMed] [Google Scholar]
  • 65.Gabler F, Nam SZ, Till S, Mirdita M, Steinegger M, Söding J, et al. Protein Sequence Analysis Using the MPI Bioinformatics Toolkit. Curr Protoc Bioinforma. 2020;72: 1–30. doi: 10.1002/cpbi.108 [DOI] [PubMed] [Google Scholar]
  • 66.Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview Version 2-A multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009;25: 1189–1191. doi: 10.1093/bioinformatics/btp033 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Karla JF Satchell

24 Oct 2021

Dear Prof Raunser,

Thank you very much for submitting your manuscript "Structure of a bacterial Rhs effector exported by the type VI secretion system" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

All three reviewers reported the significance of the work and Reviewers #1 and #3 in addition commented on the well written manuscript and technical achievement. Reviewer #2 felt more functional work up was needed to support the model while Reviewer #1 specifically notes that additional studies could be part of a future studies.

The key data that seems to be missing relates to the N-terminal cleavage site and both Reviewer #2 and #3 offer different suggestions on how to resolve either using MS or by expressing a truncated constructs. It seems that these are reasonable experiments that could be done to clarify the exact location of the N-terminal processing.These concerns should be addressed with new experiments in a revised manuscript that includes  a text revision that addresses all other comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript may be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Karla J.F. Satchell, Ph.D.

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: The manuscript by Günther et al. is a welcome addition to the field of type six secretion system (T6SS) effector biology. In this work, the authors report the high-resolution structure of the Pseudomonas protegens T6SS effector, RhsA, alone and in complex with its cognate spike protein, VgrG1. There is also an excellent comparison of all proteins containing Rhs elements of known structure (Tc toxins and teneurins). This additional comparison highlights how proteins with Rhs elements have been adapted to perform different biological functions and is an intriguing section of the manuscript (Line 239-265). The authors observe that the P. protegens RhsA forms a traditional Rhs cocoon-like shell that surrounds a C-terminal hypervariable region (HVR). As with other T6SS effectors, this HVR contains a toxin domain that mediates bacterial antagonism when delivered into a susceptible target bacterium. Autocatalytic cleavage of this toxin domain by a conserved aspartyl protease site is required for its release from the Rhs shell. The C-terminus of the Rhs shell is sealed shut in a similar manner to the Tc toxins, positioning the aspartyl protease into the interior of the shell. What is very interesting, and a novel finding, is how the RhsA shell is sealed shut at its N-terminal side. The authors observe that amino acids 268-386 form a “Plug” domain consisting of 3 parts: the Cork, Seal, and Anchor Helix. Through different hydrophobic and some hydrophilic interactions, the Cork fills in most of the space. This was nicely described as how a champagne cork would seal a bottle. The Cork is connected through a flexible region to an Anchor Helix that interacts with a specific section of the Rhs shell interior wall. The Anchor helix is then connected through another flexible region to the Seal, a peptide sequence that fills in a small gap in the Cork. They postulate that the Anchor Helix helps hold the Seal in place to close the shell. This would be an important adaptation, as the Anchor Helix and Seal are separated from the Cork between amino acids 304 and 305 by an unidentified N-terminal autocatalytic site. N-terminal processing of an Rhs protein has not been described in such detail and is an important finding for the field. Finally, the authors present the structure of RhsA, it’s cognate chaperone EagA, and its cognate spike protein VgrG1. Because of flexibility of the RhsA/EagA complex in orientation to VgrG1, the authors were unable to obtain a high-resolution structure of this entire complex but were able to present another structure of a VgrG spike. They were able to demonstrate that a VgrG trimer likely incorporates a phosphate or sulphate ion to stabilize the VgrG core. The authors put forth a model on how the RhsA toxin domain may be delivered into a susceptible targeted bacterium by the T6SS. This section relies on general knowledge of how T6SS firing events work, incorporation of studies on Tse6 (a different T6SS effector that contains a pre-PAAR motif and Trans-membrane helices), and findings from this work. While their model is sound and provides a nice conclusion to the manuscript, the exact process of toxin domain translocation across the inner membrane of a targeted bacterium has not been directly assessed for this protein; however, this aspect of the T6SS is outside the scope of this study. Overall, the manuscript is extremely well written, especially considering the technical and complex architecture of RhsA. All the figures are well designed and easy to interpret. The document was a joy to read, and I think is well suited for a broad audience. I did not observe any major concerns with this manuscript and feel that any additional experiments would be outside of the scope of this work. I did have a few minor points that I feel should be addressed prior to its final acceptance (discussed below). My congratulations to the authors for such excellent work.

Reviewer #2: The manuscript of Gunther and colleagues presents the structural analysis of type 6 secreted (T6S) effector RhsA, which shares sequence and structural features with Tc toxins and eukaryotic teneurin proteins. The large size of this protein allowed for the single particle cryo EM structure determination approach which resulted in 3.3 A resolution structure for the middle portion of the protein while the structures of N- and C-terminal portions of the protein remained mostly unresolved. The study also attempted the same structural approach for characterisation of “pre-firing” tri-protein complex of RhsA (T6S effector), EagR1 (T6S chaperon) and VgrG1 (T6S spike), which, unfortunately, did not provide on functionally important details on interactions between these proteins but provided a decent model for VgrG1 protein.

Based on this structural data the authors propose models for delivery of RhsA via interactions between N-terminal portion of the protein with T6SS machinery and for RhsA toxicity for the recipient cell via nuclease activity of C-terminal portion of the protein.

This study provides a partial molecular image of an important effector family, however it comes short of delivering significant mechanistical insight into the function of RhsA, which is expected from a molecular structure driven analysis.

This deficiency is primarily due to the lack of structural details in both N- and C-terminal portions in the presented RhsA structure, which does not allow for accurate prediction of specific elements involved in delivery via T6SS and toxic domain’s release into the cytoplasm of the recipient cell. While these shortcomings of structural data could have been compensated with an extensive functional analysis, presented functional data is very limited thus rendering proposed models of RhsA delivery and activity both over-speculative and imprecise.

To conclude, an extensive additional functional analysis addressing specific points discussed below will be needed to merit a positive review of this study.

Reviewer #3: The paper by Günther et al. describes the first structure of an RhsA-type effector exported by the Type VI secretion system (T6SS). RHS (rearrangement hotspot repeat) containing proteins were first identified in E. coli in the 1980s and for many years remained enigmatic. The function of the RHS repeat sequence in producing a cocoon-shaped protein chaperone was identified in 2013 with the structural characterisation of the BC subcomplex of the tripartite ABC toxin complexes (Tc), and around the same time, homologues of the prototypic E. coli RhsA protein were identified as being mediators of contact-dependent inhibition via the T6SS. However, the mechanistic details of how RhsA proteins function as T6SS effectors has not be clear. Hence the structure of RhsA from Pseudomonas protegens described here constitutes a significant advance in our understanding of these systems. The paper is also a technical achievement, as RhsA is at the lower end of molecular size readily visualisable by single-particle analysis (although this is mitigated by its dimerisation) and is composed entirely of β-sheet structure, which provides challenges to particle alignment.

The architecture of the RHS-repeat region, protease and C-terminal toxin regions was predictable by comparison with the BC proteins, but a major finding in this paper is the arrangement of the N-terminal region of the protein. The N-terminal domain acts as a plug capping the RHS cocoon, and unexpectedly shows a weak structural similarity (and previously undetected sequence similarity) to the equivalent domain in TcB.

The observed dimerisation of RhsA is striking on two counts. The head-to-tail dimers are initially striking for their similarity to dimers of the eukaryotic RHS-repeat containing protein Teneurin. It is also striking that this arrangement seems non-productive in the context of the T6SS. This is an issue that the authors should address. Presumably the dimer is an artefact of the isolated VgrG1-RhsA complex? Is it possible to rationalise the structure of the VgrG1-RhsA complex seen here with the T6SS spike structure reported by Nazarov et al. (doi.org/10.15252/embj.201797103) ?

Although it builds on previously published work, the delivery model suggested in Figure 6 is the most speculative part of the paper, and does not seem fully supported by the available data. It is unclear how two trans-membrane helices will be sufficient to form a pore able to translocate a polypeptide through the inner membrane. Is it possible that inner membrane proteins in the target cell are also required? It is additionally unclear how the T6SS contractile event does not simply push the sharp PAAR tip through the inner membrane. Not all PAAR-containing effectors contain a TM-helix-containing pre-PAAR domain, which implies at least the existence of an alternate mechanism.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: None

Reviewer #2: Both N- and C-terminal portions of RhsA effector undergo autocleavage as have been shown for other members of this family (Pei et al., 2020). Current study attempts to use obtained RhsA structure to gain insight into both these processes but fails to deliver. This shortcoming should be addressed via appropriate functional assays.

The mechanism of C-terminal portion cleavage appears to be similar to the process described for the Tc toxins and previously characterised representatives of this family. The authors suggest that the C-terminal portion cleavage can be abrogated via mutations of conserved catalytic residues, that are validated by the competition assay (Fig 2C). However, the overexpression of the same mutants in the assay presented at Supp Fig 3E suggests that these mutants retain some (less than the wild type) toxicity. Why isn’t this toxicity manifesting in the competition assay? The biochemical activity of C-terminal toxin is only implied via sequence similarity but never tested. Is the activity of C-terminal domain inhibited by the appropriate immunity protein? The presence of immunity protein often helps stabilizing and obtaining the structure of toxic domain. Was this attempted?

Presented effort for gaining insight into RhsA’s N-terminal portion’s cleavage is even less convincing. The specific position of the cleavage is determined based on the absence of interpretable density after residue 305, which is not particularly accurate and can also be due to lability of this portion of the structure. There are specific mass spectrometry based assays that should be used to identify/confirm the specific position of N-terminal cleavage. Wrongly estimated cleavage site could be one of possible reasons for failing to identify the catalytic residues responsible for auto-proteolysis of N-terminal portion. Obtaining non cleavable version of RhsA could have provided insights into this mechanism. Since the mutation of “usual suspects” did not reveal the culprits more unbiased approach (alanine scanning mutagenesis?) must be applied.

The model proposed for conformational changes of RhsA upon delivery by T6SS into recipient cell (Fig. 6) is by far the weakest and most over-speculative part of this study. Primarily based on experimentally unconfirmed position of the cleavage site it liberally uses analogy with Tc toxin while continuously highlighting the significant differences between these proteins and RhsA. Since no structural or functional data is provided in support of this model, I see no way of assessing its merit. Just to provide a specific example, provided model suggests that the 2 predicted transmembrane helices will facilitate the threading and/or translocation of either toxin or the entire cocoon/toxin portion through the inner membrane into recipient cell’s cytoplasm. Would authors provide an example of a translocation channel composed with only 2TMs that their model is based on? Any experimental assays tried to show the formation of such translocation channel by these 2 TMs?

Reviewer #3: The autoproteolysis of the N-terminal domain is a significant new finding. Frustratingly, mutation of the identified possible active site residues for the protease activity (e.g. C538) does not alter protease activity. It is therefore suggested that the encapsulated toxin contributes active site residues for the protease activity. Given that the C-terminal toxin domain is unfolded within the cocoon, it seems unlikely that it can contribute active site residues to the proteolytic cleavage. However, this idea is testable: Is the N-terminal domain cleaved if a truncated protein lacking the C-terminal toxin is expressed? This is a relatively straightforward experiment that should be performed.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: 1. Figure 2C, y-axis: I just want to clarify that this is the Log10 of the Competitive Index as calculated in the methods, i.e. Log10((Donor CFU/Recipient CFU)endpoint / (Donor CFU/Recipient CFU)beginning). Perhaps just clarify in the methods.

2. Figure 2G, RhsA∆N: I could not find a exact definition of this construct. Based on the main text line 169, I’m assuming it is an N-terminal deletion of RhsA at AA305, but I wound define this either in the legend or in the main text.

3. Supplementary Figure 3C: Should residue 313 be a K not an A?

4. Supplementary Figure 3H: There is also impaired cleavage of the H530A construct, but this was not mentioned in the text. This residue is highlighted in Supplementary Figure 3G, and thus seems like an important residue to comment on. This construct also appears to have a majority of -CT bands, not +CT bands, where the D318A/D319A/D320A construct has a mixture of both. Is there a possible relation of this N-terminal region to C-terminal cleavage? This may be an instance where further experiments are outside the scope of this manuscript, but I think it may be worth a comment.

5. Sentences from line 333 to 338. I think this appears to be the most plausible scenario. What is not hypothesized here is how the N-terminal TM helices, which have been cleaved from the Rhs shell, may subsequently interact with the C-terminal toxin as it leaves the Rhs shell through the opened seal. Would you propose that the Shell and TM helices come together to funnel the toxin across the inner membrane, or do you see release of the toxin from the Rhs shell as a separate event from membrane translocation (i.e. the toxin has to “find” the TM helices to translocate across the inner membrane). I understand this section is a proposed model, but it may be strengthened by a bit more explanation.

Reviewer #2: Given the important similarity between RhsA and Tc toxins/ teneurin discussed throughout the manuscript more information about these proteins must be provided in the introduction.

L-62-63: “latter likely plays a role in target in cell penetration”. In the context of this sentence “latter” refers to transmembrane helices while the cell penetration is rather function of VgrG spike, no? Consider rewording.

L-74: “Tc toxin”. – As per my general comment above the Tc toxin needs proper introduction/explanation prior to this statement.

L-134: Supp Fig 3C-E. Should be corrected to Supp Fig 3B.

L-151: Is the functional prediction based on structural similarity or primary sequence features?

L-246-249: “hyperconserved region”. I am not sure there is such a term. Earlier in introduction, C-terminal part of Rhs is mentioned as “hypervariable region”, but within this domain there is hyperconserved region?

Fig 3C: Is it teneurin structure presented here? If so, please add the proper statement to the legend as the title for Fig 3 refers to RhsA structure. From main text, it appears to be the teneurin structure

L-309: “After cleavage…” Is it after cleavage that EagR1 binds to N-terminal TM or is it before? From Fig6, it looks like EagR1 binds before the cleavage.

L-327: “As proposed previously…” Appropriate reference is needed.

Reviewer #3: Line 79: It’s not clear what is meant by “host cell targeting”.

Line 93 and elsewhere: RHS repeats do not form a β-barrel, which is a specific defined protein topology where β-sheets form a closed toroid distinguished by continuous hydrogen bonds between strands. In contrast RHS repeats form an extended β-sheet which is folded around onto itself. This is best described as a “cocoon “or a “shell” instead.

Line 168-169 -ΔN and ΔNT is somewhat confusing terminology

Line 226: The phrase “Rhs core” has been used previously in the published literature to refer to hyperconserved autoprotease region. Here the cocoon is referred to as the “core”, which is potentially confusing.

Lines 752-756 Should the PDB and EMDB IDs be listed?

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes: J. Shaun Lott

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 1

Karla JF Satchell

8 Dec 2021

Dear Prof Raunser,

We are pleased to inform you that your manuscript 'Structure of a bacterial Rhs effector exported by the type VI secretion system' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Karla J.F. Satchell, Ph.D.

Section Editor

PLOS Pathogens

Karla Satchell

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

Acceptance letter

Karla JF Satchell

31 Dec 2021

Dear Prof Raunser,

We are delighted to inform you that your manuscript, "Structure of a bacterial Rhs effector exported by the type VI secretion system," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Cryo-EM processing workflow used to obtain the structure of RhsAΔTMD.

    (A) Purification of RhsAΔTMD via size-exclusion chromatography using a Superose 6 5/150 increase column. Molecular weight standards are indicated at their respective elution volumes. The grey bar denotes pooled and concentrated fractions used for cryo-EM analysis. The same material was analyzed for purity via semi-denaturing SDS-PAGE imaged with a stain-free filter. (B) Representative cryo-EM micrograph of RhsAΔTMD used for structural determination. Scale bar EM micrograph, 100 nm. Particles were picked with the general model of crYOLO. The rest of the processing workflow is indicated and summarized in the Materials and Methods section. Scale bar 2D class averages, 10 nm. Used software packages are highlighted. Orange font depict steps carried out in Relion. The final map was calculated using MERIDIEN and postprocessed with DeepEMhancer. (C) Angular distribution plot of the final reconstruction. (D) Local resolution estimates visualized on a map postprocessed in SPHIRE. (E) Fourier shell correlation plot calculated from two independently processed maps. Resolution estimation is reported at the gold standard cutoff of 0.143. (F) Resolution anisotropy was assessed with the 3DFSC online server tool. (G) Selected regions of the map are shown as transparent surface with the built atomic models as stick representations.

    (TIF)

    S2 Fig. Structural analysis of the dimer interface of RhsA.

    (A) Close up view of the dimer interface of the two RhsA molecules at the central symmetry axis. Potential candidate residues engaging in stabilizing interactions are labelled and shown in stick representation. (B) Surface properties of the dimer interface and the periphery of RhsA. The surface of the interface is colored according to its Coulomb potential indicating positively (red, -20) and negatively (blue, +20) charged areas. The second representation shows the same interface but colored according to hydrophobicity. Ochre indicates hydrophobic and white indicates hydrophilic regions. The area facing the outer peripheries of both barrels shows that these regions would electrostatically repel each other and explain why only two barrels can interact at the same time.

    (TIF)

    S3 Fig. Characterization of the C-terminal autoproteolysis site of RhsA.

    (A) Multiple sequence alignment of the C-terminal cleavage site. The cleavage site is indicated by the black arrow. Critical residues are highlighted by the residue numbering. Coloring is according to the ClustalW color code. (B) In E. coli toxicity assays show reduced toxicity of RhsAΔTMD harboring mutations of the catalytic aspartates D1324N and D1346N, respectively. Toxicity could by reversed by overexpression of the immune protein RhsI. The lower panel represents the same toxicity assay but with lower RhsA expression levels due to lower inducer concentration (L-rhamnose).

    (TIF)

    S4 Fig. Local environment of the ordered toxin fragments inside the Rhs cocoon.

    Interaction of three β-strands belonging to the toxin domain of RhsA with the Rhs barrel. The toxin fragments are stabilized by the interaction with hydrophobic and hydrophilic surfaces inside the Rhs barrel. The molecular surface is colored according to hydrophobicity with ochre and white indicating hydrophobic and hydrophilic regions, respectively. The electrostatic representation is colored according to Coulomb potential, which depicts positively (red, -20) and negatively (blue, +20) charged areas.

    (TIF)

    S5 Fig. Characterization of the N-terminal autoproteolysis site of RhsA.

    (A) The N-terminal cleavage site was identified by protein sequencing. The band containing the Rhscage was excised and analyzed by de novo protein sequencing using LC-MS/MS. (B) Western blot analysis of wild-type or a N-terminal cleavage resistant mutant (H304A/P305A) confirming the location of the cleavage site at P305. (C) Multiple sequence alignment of the N-terminal cleavage site. The cleavage site is indicated by a black arrow. Coloring is according to the ClustalW color code. (D) Sequence alignment of the T6SS class I prePAAR effectors highlighting the N-terminal cleavage site. Residue conservation is depicted as Weblogo. The Weblogo represents residue conservation. (E) Cartoon representation of the N-terminal cleavage site in RhsA. Residues A312 and K313 as well as conserved and potential catalytically active residues are show in stick representation. Residues A312 and K313 correspond to the catalytically active glutamates in TseI [18]. (F) Hypothesized cysteine protease motif which is near the N-terminal cleavage site P305. (G) Multiple sequence alignment highlighting the conservation of the hypothesized cysteine protease motif among class I prePAAR effectors. The Weblogo represents residue conservation. (H) Western blot analysis of potential residues involved in N-terminal cleavage and generation of the cleavage product RhsAN. Impaired cleavage was assessed by appearance of the full-length RhsA chain which is a mixture of both species, the C-terminally cleaved fragment (-CT) and the C-terminally uncleaved fragment (+CT). RhsA was coexpressed with its cognate chaperone EagR1. The blot was performed against N-terminal His6-tagged proteins (α-His). (I) Western blot analysis to examine the potential involvement of RhsA’s C-terminal toxin domain in the autoproteolysis of its N-terminal region. An RhsA truncation lacking the C-terminal toxin domain (RhsAΔtox, residues 1–1323) was expressed and examined for N-terminal cleavage using antibodies that recognize its N-terminus (α-FLAG) or its Rhs cocoon (α-RhsA).

    (TIF)

    S6 Fig. Hydrophilic interactions of the plug domain with the Rhs barrel.

    (A) Only a few hydrophilic interactions stabilize the plug domain. Residues participating in hydrogen bonds are labeled and shown in stick representation. The cork and the seal are colored in orange whereas the Rhs repeats is colored in beige. (B) The barrel would not be closed without the observed density corresponding to the seal. The model for the seal was manually removed to visualize the opening though which toxin is threaded into the target cell after removal of the seal and the anchor helix.

    (TIF)

    S7 Fig. Stabilization of the N-terminal seal and anchor helix of RhsA.

    (A-B) A small density, corresponding to seal (residues K268-V275) of RhsA enters the barrel from the top (mesh). This results in a complete sealing of the cocoon. (C–E) The seal leads further down into an amphipathic helix which strongly interacts with the inner surface of the cocoon and thus serves as an anchor point for the N-terminal domain. The amphipathic helix is stabilized by hydrophobic interactions with Rhs repeats.

    (TIF)

    S8 Fig. Comparison of Rhs repeat containing proteins of known structure.

    (A) Comparison of the plug domains of RhsA (orange) with YenBC (PDB ID: 4IGL), TcdB2-TccC3 (PDB ID: 6H6G) and Ten2CT (PDB ID: 6FB3). (B) Sequence alignment of the plug domain of RhsA with the sequences of the homologous domains found in TcdB2-TccC3 (top) and YenBC (bottom) are shown. Residues are colored according to the ClustalW color code. (C) Structural overlay of RhsA with YenBC (left) and Ten2CT (right).

    (TIF)

    S9 Fig. Cryo-EM of the PFC.

    (A) Representative negative stain micrograph and 2D class averages of the intact PFC consisting of VgrG1, RhsA and EagR1. Scale bar micrograph, 100 nm. Scale bar 2D class averages, 10 nm. (B) Cryo-EM micrograph of the PFC and image processing workflow. Particles were picked with the general model of crYOLO and classified with ISAC. Refinement in MERIDIEN led to a reconstruction of 3.3 Å (FSC = 0.143 criterion). The final reconstruction was either colored individually for each protomer or according to local resolution. Fourier shell correlation was plotted according to two independent refined maps. Dashed line indicates the gold standard FSC criterion of 0.143. Scale bar micrograph, 100 nm. Scale bar 2D class averages, 10 nm. (C) Overlay of VgrG1 from P. protegens (green) with VgrG1 from P. aeruginosa (blue, PDB ID: 6H3N). (D) Map quality of selected parts of the structure (transparent surface) with built atomic models (cartoon representation). (E) Potential ion binding site in the middle part of the β-prism of P. protegens VgrG1. Sulfate ions were modelled into the spherical densities. Coordinating residues are displayed in stick representation.

    (TIF)

    S1 Table. Bacterial strains used in this study.

    (DOCX)

    S2 Table. Plasmids used in this study.

    (DOCX)

    S1 Movie. Flexibility of the VgrG1-RhsA-EagR1 complex.

    This video highlights the positional flexibility of RhsA relative to the VgrG1 spike protein.

    (MP4)

    S1 Dataset. Dataset of de novo protein sequencing of RhsA.

    (ZIP)

    Attachment

    Submitted filename: Author_Response.docx

    Data Availability Statement

    The cryo-EM maps of VgrG1 and RhsA have been deposited in the Electron Microscopy Data Bank (EMDB) under the accession codes of EMD-13843 and EMD-13867, respectively. The refined models for VgrG1 and RhsA were uploaded in the PDB and the entries have the IDs 7Q5P and 7Q97, respectively. The original data of the de novo protein sequencing is available inprovided as supplementary data (the S1 Dataset).


    Articles from PLoS Pathogens are provided here courtesy of PLOS

    RESOURCES